Storia in 2 fonti

UK biotech secures $115M to advance portfolio of virus-targeting antibodies

RQ Bio has clinched $115 million in a Series A raise to advance a preclinical pipeline of virus-targeting antibodies.

Raccontata da

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 mese fa

RQ Bio has clinched $115 million in a Series A raise to advance a preclinical pipeline of virus-targeting antibodies.

The startup claims to have a “differentiated” antibody that can provide long-lasting protection against a variety of influenza strains.